AU2494499A - Compositions and methods for modulating cytokine release in response to genotoxic agents - Google Patents

Compositions and methods for modulating cytokine release in response to genotoxic agents Download PDF

Info

Publication number
AU2494499A
AU2494499A AU24944/99A AU2494499A AU2494499A AU 2494499 A AU2494499 A AU 2494499A AU 24944/99 A AU24944/99 A AU 24944/99A AU 2494499 A AU2494499 A AU 2494499A AU 2494499 A AU2494499 A AU 2494499A
Authority
AU
Australia
Prior art keywords
dna
protein kinase
agent
genotoxic
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24944/99A
Other languages
English (en)
Inventor
Daniel B Yarosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genetics Inc
Original Assignee
Applied Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genetics Inc filed Critical Applied Genetics Inc
Publication of AU2494499A publication Critical patent/AU2494499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU24944/99A 1998-02-04 1999-02-04 Compositions and methods for modulating cytokine release in response to genotoxic agents Abandoned AU2494499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7364098P 1998-02-04 1998-02-04
US60073640 1998-02-04
PCT/US1999/002348 WO1999039720A1 (en) 1998-02-04 1999-02-04 Compositions and methods for modulating cytokine release in response to genotoxic agents

Publications (1)

Publication Number Publication Date
AU2494499A true AU2494499A (en) 1999-08-23

Family

ID=22114913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24944/99A Abandoned AU2494499A (en) 1998-02-04 1999-02-04 Compositions and methods for modulating cytokine release in response to genotoxic agents

Country Status (7)

Country Link
EP (1) EP1052998A4 (de)
JP (1) JP2002502820A (de)
CN (1) CN1296413A (de)
AU (1) AU2494499A (de)
CA (1) CA2319567A1 (de)
IL (1) IL137253A0 (de)
WO (1) WO1999039720A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135583T1 (de) * 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen

Also Published As

Publication number Publication date
EP1052998A4 (de) 2003-02-26
CN1296413A (zh) 2001-05-23
CA2319567A1 (en) 1999-08-12
WO1999039720A1 (en) 1999-08-12
EP1052998A1 (de) 2000-11-22
IL137253A0 (en) 2001-07-24
JP2002502820A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
Oliver et al. Drug resistance in glioblastoma: are persisters the key to therapy?
Ferrara-Romeo et al. The mTOR pathway is necessary for survival of mice with short telomeres
Beck et al. Drug resistance associated with altered DNA topoisomerase II
Liu et al. A novel poly (ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
Abeyama et al. A role for NF-κB–dependent gene transactivation in sunburn
Kharbanda et al. Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents
HU229263B1 (en) The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
Hou et al. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
Little et al. Focus: skin: cutaneous lupus erythematosus: current and future pathogenesis-directed therapies
Habib et al. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by rapamycin-mediated AMPK activation and mTOR inhibition
Jin et al. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase.
Windhofer et al. Marked dependence on growth state of backup pathways of NHEJ
Rather et al. Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma
Rousseau et al. Gain-of-function mutations in the toll-like receptor pathway: TPL2-mediated ERK1/ERK2 MAPK activation, a path to tumorigenesis in lymphoid neoplasms?
Sabi et al. Elucidating the role of hypoxia-inducible factor in rheumatoid arthritis
EP1025237A2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
Pandya et al. PICOT (GLRX3) is a positive regulator of stress-induced DNA-damage response
WO2007143629A1 (en) Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
Gullotta et al. Targeting the DNA double strand breaks repair for cancer therapy
Kasten et al. Ku70/80 gene expression and DNA-dependent protein kinase (DNA-PK) activity do not correlate with double-strand break (dsb) repair capacity and cellular radiosensitivity in normal human fibroblasts
Nandi et al. YY1 control of mitochondrial‐related genes does not account for regulation of immunoglobulin class switch recombination in mice
Mijit et al. Activation of the integrated stress response (ISR) pathways in response to Ref-1 inhibition in human pancreatic cancer and its tumor microenvironment
Booth et al. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells
AU2494499A (en) Compositions and methods for modulating cytokine release in response to genotoxic agents
Enns et al. Effects of the protein kinase inhibitors wortmannin and KN62 on cellular radiosensitivity and radiation-activated S phase and G1/S checkpoints in normal human fibroblasts

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted